
**What is Claimed:**

1. A pharmaceutical formulation comprising a KZR-616 maleate salt~~or a salt~~ ~~thereof~~, and a sugar, wherein KZR-616 has a structure  , the sugar comprises trehalose, and the formulation is a lyophilized formulation.

~~2. The formulation of claim 1, wherein KZR-616 is as a maleate salt.~~

~~3.~~2. The formulation of claim 1 ~~or 2~~, having a pH of 3.0 to 4.5, as measured prior to lyophilization.

~~4.~~3. The formulation of claim 2~~3~~, having a pH of 4.2.

~~5.~~4. The formulation of any one of claims 1 to 3~~4~~, further comprising a succinate buffer.

~~6.~~5. The formulation of any one of claims 1 to 4~~5~~, wherein the KZR-616 ~~or a salt thereof~~ is present in an amount of 100 mg/mL to 200 mg/mL based upon the weight of the KZR-616 free base.

~~7.~~6. The formulation of any one of claims 1 to 5~~6~~, wherein the sugar is present at an amount of 1.5wt% to 3 wt%, based upon total weight of the formulation.

~~8.~~7. The formulation of any one of claims 1 to 6~~7~~, wherein the sugar further comprises mannitol~~, trehalose, or a combination thereof~~.

~~9. The formulation of claim 8, wherein the sugar comprises trehalose.~~

~~10.~~8. The formulation of any one of claims 1 to ~~9~~7, wherein the lyophilized formulation has a moisture content of less than 1%.

~~11.~~9. The formulation of any one of claims 4 to ~~10~~8, having a pH of 4.1 to 4.3 (as measured when reconstituted) after storage at 5°C, 25°C, or 40°C for at least six months.

~~12.~~10. The formulation of any one of claims 1 to ~~11~~9, having a reconstitution time of less than 4.5 minutes after storage at 5°C, 25°C, or 40°C for at least six months.

~~13.~~11. The formulation of any one of claims 1 to ~~12~~10, wherein the lyophilized formulation has a moisture content of less than 1% after storage at 5°C, 25°C, or 40°C for at least six months.

~~14.~~12. The formulation of any one of claims 1 to ~~13~~11, wherein the KZR-616 ~~or a salt thereof~~ is at least 93% pure after storage at 5°C, 25°C, or 40°C for at least six months.

~~15.~~13. A reconstituted formulation comprising the formulation of any one of claims 1 to ~~14~~ 12 and a solvent for reconstitution.

~~16.~~14. The reconstituted formulation of claim ~~15~~13, wherein the solvent for reconstitution comprises water for injection (WFI) or aqueous 5% dextrose.

~~17.~~15. The reconstituted formulation of claim ~~15~~ 13 or ~~16~~ 14 having an osmolality of 275 to 325 mOsm.

~~18. The reconstituted formulation of any one of claims 15 to 17, having an absorption rate, as measured by $T_{1/2}$, of at least 50% faster than that of a formulation comprising KZR-616 or salt thereof and polysorbate-80.~~

~~19. The reconstituted formulation of any one of claims 15 to 18, having a $C_{max}$ of at least 150% that of a formulation comprising KZR-616 or a salt thereof and polysorbate-80 ("PS-80 formulation").~~

~~20.~~16. The reconstituted formulation of any one of claims ~~15~~ 13 to ~~19~~15 for use in the treatment of lupus nephritis or systemic lupus erythematosus (SLE)~~an immune-related disease~~.

~~21. The reconstituted formulation for use of claim 20, wherein the immune-related disease is lupus nephritis or systemic lupus erythematosus (SLE).~~

~~22.~~17. The reconstituted formulation of any one of claims ~~15~~ 13 to ~~19~~15 for use in the treatment of inflammation.